Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
Pharmather announces receiving a patent from the USPTO for its "ketamine flow synthesis". Pharmather has exclusive worldwide development and commercial rights to this IP.
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.
Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.